SAS Output

23-JAN-2018 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1490 347 159 91 29 4 07/08/2014 443 221
            1490 347 159 91 29 4      
 
    2 Y 17 S1400G   43 43 15 11 3 1      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        21 S1400F   21 21 21 18 5 0      
        3 S1400B   53 0 0 0 0 0      
        4 S1400C   88 0 0 0 0 0      
        5 S1400D   92 0 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   671 233 91 38 13 5      
            1144 297 127 67 21 6      
 
    3 P 10 S1400I   10 4 3 2 1 1      
        18 S1400G   8 8 2 0 0 0      
        22 S1400F   4 4 4 4 1 1      
        8 S1400B   1 0 0 0 0 0 07/08/2014    
            23 16 9 6 2 2      
 
    4 P 23 S1400F   1 1 1 1 1 1 07/08/2014    
            1 1 1 1 1 1      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014    
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 4 3 1 0 0 0 07/31/2014    
            4 3 1 0 0 0      
 
  S1400F-Non-Match: MEDI4736 + Tremelimumab 1 Y 1 MEDI4736 + Tremelimumab 132 6 6 6 6 1 1 11/30/2017   214
            6 6 6 6 1 1      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 35 35 11 5 2 1 03/03/2017 441 220
            35 35 11 5 2 1      
 
  S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 350 130 49 27 13 4 1 12/29/2015 440 220
        2 Nivolumab   126 47 18 6 1 0      
            256 96 45 19 5 1      
 
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 1 Y 1 AFATINIB + CETUXIMAB 605 79 38 14 6 0 0 05/07/2015 223 94
        2 AFATINIB   81 41 16 9 4 1      
            160 79 30 15 4 1      
 
  S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 1 Y 1 Trametinib + Docetaxel 53 53 40 16 12 3 1 10/05/2016 208 93
            53 40 16 12 3 1      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 N 5 RT+Pac+Carbo+blinded drug 132 18 15 4 0 0 0 01/24/2013 111 51
        6 RT+Pac+Carbo+blinded drug   14 11 2 0 0 0      
            32 26 6 0 0 0      
 
    2 Y 8 Pac + Carbo + blinded drug 132 23 22 11 4 0 0 01/24/2013    
            23 22 11 4 0 0      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   33 19 9 5 1 0 04/01/2015   247
            33 19 9 5 1 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   425 200 95 42 9 3 12/16/2014 451 251
            425 200 95 42 9 3      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   55 5 4 3 0 0 05/14/2008 230 117
            55 5 4 3 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   7 4 3 1 0 0 02/29/2016 467 260
            7 4 3 1 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 3 1 0 0 0 10/20/2016 329 142
            4 3 1 0 0 0      
 
    2 E Total Registrations   4 3 1 0 0 0 10/20/2016    
            4 3 1 0 0 0      
 
  R1306-NSCLC,Adv,ALK/EGFR,TargetAgents 1 E Total Registrations   8 0 0 0 0 0 03/12/2014 188 77
            8 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   431 202 95 41 8 3 12/16/2014 451 251
            431 202 95 41 8 3      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   35 29 21 11 5 3 08/03/2016 410 235
            35 29 21 11 5 3      
 

23-JAN-2018 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC 1 Neoadjuvant Therapy 03-Nov-17
  2 Surgery 03-Nov-17
  3 Maintenance 03-Nov-17